Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.LIMR wins Bill & Melinda Gates Foundation grant
LCGC president, CSO and founder Melvin Reichman will begin a new global health and development research project, titled "A Totally New Approach to Discover Malaria Combination Drugs.” Reichman
LCGC president, CSO and founder Melvin Reichman will begin a new global health and development research project, titled "A Totally New Approach to Discover Malaria Combination Drugs.” Reichman
The trial used a previously developed method to integrate ischemic and bleeding events as "ischemic stroke equivalents" to compare weighted benefit of two doses of dabigatran with each
The NOA, which is issued based on the 12/986,389 and 13/230,084 applications, will enable the company to receive patents for interfering RNA molecules and lipid complexes. The claims
Under the contract, Hemp will have exclusive worldwide marketing rights for 3 years and non-exclusive marketing rights for 20 years to products derived from cannabis or hemp and
Harmoni services include Out of Hours, 111, prisoner healthcare and IT services, which provide services to over eight million people in the UK. Harmoni is a spinoff company
Ildong will distribute the weight loss or weight management drug subsequent to the Korea Food and Drug Administration (KFDA) approval. Arena president and chief executive officer Jack Lief
Under the license agreement, the technology, which will be part of BioLight’s ophthalmic cluster, will be used by ViSc to further develop a sub-conjunctival drug implant for the
Total revenue for third quarter of 2012 was $55.77m, an increase of 11%, compared to $50.23m for the third quarter of 2011. The company reported a net loss
Xeljanz can be used as a single treatment regime or as combination therapy with standard methotrexate or any non-biologic disease-modifying antirheumatic drugs (DMARDs). Pfizer chairman and chief executive
Revenues for third quarter of 2012 were $577,759 compared to $147,122 for the third quarter of 2011. The company reported a net loss of $4.04m, or $0.05 per